<DOC>
	<DOCNO>NCT02502968</DOCNO>
	<brief_summary>This study evaluate addition BL-8040 standard consolidation therapy cytarabine treatment acute myeloid leukemia ( AML ) adult . Half participant receive BL-8040 cytarabine combination , half receive placebo cytarabine .</brief_summary>
	<brief_title>BL-8040 Addition Consolidation Therapy AML Patients</brief_title>
	<detailed_description>The majority AML patient first complete Remission ( CR ) relapse despite current consolidation therapy . Leukemic stem cell dormant bone marrow presume major reason AML relapse . Allogenic stem cell transplantation option minority AML patient 1st CR . BL-8040 novel CXCR4 inhibitor dual mechanism action : inducing mobilization leukemic blast bone marrow enhances cytotoxic effect chemotherapy direct antileukemic , pro-apoptotic property . The treatment BL-8040 combination consolidation therapy ( standard consolidation high-dose cytarabine ) improve efficacy consolidation therapy result long lasting remission .</detailed_description>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<criteria>Histologically morphologically confirm diagnosis AML except AML M3 ( acute promyelocytic leukemia ) AML achieve complete remission ( CR ) , include CRi CRp maximum number 2 cycle induction chemotherapy . AML subject young 60 year time diagnosis intermediate highrisk cytogenetics ECOG performance status ≤2 Laboratory value follow ( time randomization ) : WBC &lt; 30.000/μl &gt; 1000/μl , Platelets count &gt; 70.000/μl , Creatinine &lt; 1.0 mg/dl . If creatinine 1.0mg/dl 1.3mg/dl , creatinine clearance &gt; 30ml/min calculate use CockroftGault formula Women childbearing potential must practice acceptable method birth control 6 month last dose treatment . Female subject lactate must discontinue nurse prior first dose study drug refrain nursing throughout treatment period 14 day follow last dose study drug . Male female partner childbearing potential use barrier method contraception Written inform consent Subject able willing comply requirement protocol . Relapsed refractory AML Start induction cycle &gt; 90 day randomization . Subjects receive &gt; 2 cycle induction chemotherapy AML therapy . Subjects young 60 year time diagnosis favorable cytogenetics ( ( 8 ; 21 ) inv ( 16 ) ( 16 ; 16 ) ( 15 ; 17 ) ) confirm presence result fusion protein AML1ETO , CBFBMYH11 PMLRARA . Subjects allogeneic HSCT plan CR1 . Planned maintenance therapy end protocol define consolidation therapy . Known allergic hypersensitivity BL8040 cytarabine test compound , material Use investigational device agent within 2 week less 5 half lifes investigational product /device time enrolment . Registry study permissible . Abnormal liver function test : Serum AST/ GOT ALT/ GPT &gt; 3x upper limit normal ( ULN ) , Serum bilirubin : Total bilirubin &gt; 2.0mg/dl , conjugate bilirubin &gt; 0.8mg/dl O2 saturation &lt; 92 % ( room air ) Concurrent , uncontrolled medical condition , laboratory abnormality , psychiatric illness could place subject unacceptable risk Another malignancy within 3 year enrolment , except situ malignancy , lowrisk prostate , skin cervical cancer curative therapy . History cancer accord Investigator might confound assessment endpoint study . A comorbid condition , view Investigators , render subject high risk treatment complication . History follow cardiovascular condition : cardiac angioplasty ( within 6 month ) stenting ( within 6 month ) and/or myocardial infarction ( MI ) ( within 6 month ) cerebrovascular event within past 6 month , unstable angina , vascular disease , class III IV , congestive heart failure ( defined New York Heart Association ( NYHA ) ) Known central nervous system disease may jeopardize subject 's study participation accord investigator judgement Active , uncontrolled infection . Prior clinically significant grade 34 nonhematological toxicity highdose cytarabine grade ≥ 2 neurological toxicity Positive serology HIV , active Hepatitis C Hepatitis B ( HBsAG pos . ) baseline Left ventricular ejection fraction ( LVEF ) &lt; 40 % multiple gated acquisition ( MUGA ) scan echocardiogram ( ECHO ) baseline Subjects psychological , psychiatric , neurological , familial , sociological , geographical condition permit compliance protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>